Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Agilent Technologies Inc. A, -3.03% rose more than 5% in the extended session Wednesday after the maker of lab instruments and other components reported fiscal third-quarter profit and sales above Wall Street expectations and tweaked its guidance for the year.

Agilent stock rises after earnings beat, raised guidance

Agilent Technologies (NYSE: A) unveils its next round of earnings this Wednesday, August 14.

Q3 Earnings Preview For Agilent Technologies

Applied Optoelectronics

Apple

Ebix

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

The Truth About Market Timing - July 30, 2019

Agilent has transformed its business since spinning-off from Hewlett Packard in 1999.

Agilent: 2 Decades Of Portfolio Moves Left Investors With A Good Business

Agilent Technologies (A) enters into an agreement to buy BioTek Instruments, which is likely to strengthen its cell analysis capabilities and expand presence in life science research space.

Agilent to Acquire BioTek, Cell Analysis Portfolio to Expand

Agilent (NYSE: A) will acquire BioTek Instruments in a $1.165 billion deal. The transaction is expected to be completed in Agilent’s fiscal fourth quarter.

Agilent Will Acquire BioTek Instruments In $1.16B Deal

Life sciences company Agilent Technologies Inc.  said Thursday it has agreed to acquire privately held BioTek Instruments for $1.165 billion.

Agilent to acquire privately held BioTek instruments for $1.165 billion

Agilent is in attractive markets and has growth levers in place with new products.

Agilent: An Excellent Company At Average Price

Avantor Inc.

Danaher

Thermo Fisher Scientific

Investing in the life sciences tool sector can be tricky, but according to the financial services firm Janney, the investing gain will be a result of finding the right secular trend in its own sector that comes from exposure to the production of biological therapeutics.

One Firm Sees Up to 45% Upside in Top Companies in Life Sciences Tools

Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.

Agilent Announces Receipt of FDA Approval for pharmDX Assay

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Why Is Agilent (A) Up 3.9% Since Last Earnings Report?

Shifting market dynamics stung the business in the fiscal second quarter.

Here's Why Agilent Technologies Fell 14.6% in May

A stolen N.S.A. hacking tool was a component in a cyberattack on the city, people involved in the investigation have told The Times.

N.S.A. Denies Its Cyberweapon Was Used in Baltimore Attack, Congressman Says

Medical device company Soliton, Inc. (NASDAQ: SOLY) reacted Friday to a blog post calling the firm a "PR machine" and addressed whether it can achieve Food and Drug Administration clearance to market its new Rapid Acoustic Pulse technology.

Soliton Responds To Blog Calling It A 'PR Machine'

Investors willing to bet the much-maligned value factor is poised to rebound can do so with a new, unique exchange traded fund.

A New ETF To Refresh The Value Factor

The lab equipment and services provider reduced full-year fiscal 2019 revenue guidance. Is today's tumble just a big overreaction?

Here's Why Agilent Tumbled Today

Agilent (A) reports weak fiscal second-quarter results due to slowing global demand in small molecule Pharma and softness in the China Food market.

Agilent (A) Misses Earnings and Revenue Estimates in Q2

Agilent Technologies, Inc. (A) CEO Mike McMullen on Q2 2019 Results - Earnings Call Transcript

Agilent Technologies (A) posted its latest quarterly earnings results after hours today, bringing in a profit that missed analysts' guidance.

Agilent Technologies Earnings: A Stock Sinks on Q2 EPS, Sales Miss

Agilent (A) delivered earnings and revenue surprises of -1.39% and -2.30%, respectively, for the quarter ended April 2019. Do the numbers hold clues to what lies ahead for the stock?

Agilent Technologies (A) Q2 Earnings and Revenues Miss Estimates

Shares of Agilent Technologies Inc.  fell more than 9% in the extended session Tuesday after the lab-instrument maker reported fiscal second-quarter results that missed Wall Street expectations and revised its full-year sales outlook.

Agilent stock tanks after company's quarterly miss, revised outlook

Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Agilent Technologies Stock (A)